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Background
Combination treatment with all-trans-retinoic acid (ATRA) and anthracycline-based che-
motherapy has led to major advances in the treatment of acute promyelocytic leukemia 
(APL). 
Methods
In this study, we reviewed the outcome of pediatric APL patients treated using a modified 
AIDA protocol at our institution.
Results
Between May 1999 and December 2007, 23 patients were diagnosed with APL at the 
Department of Pediatrics, Saint Mary’s Hospital, The Catholic University of Korea. Eleven 
patients were male (48%) (median age at diagnosis, 11 (range, 2-14) years). The treatment 
protocol consisted of remission induction (achieved by coadministration of ATRA and 
idarubicin), 3 courses of consolidation treatment, and 2 years of maintenance treatment 
during which ATRA was also administered. Three patients died early during remission 
induction due to CNS hemorrhage. The remaining 20 patients achieved complete re-
mission (CR), with an overall CR rate of 87%. Two patients relapsed and died, and another 
patient died of pneumonia unrelated to APL. Four patients (17%) were diagnosed with 
ATRA syndrome, and all patients showed resolution of symptoms. The event-free survival 
(EFS) and overall survival (OS) of the cohort were 78.3±8.6% and 76.3±9.5%,
respectively. Initial WBC count at diagnosis was the only significant prognostic factor for 
the rate of CR (P=0.039) and OS (P=0.039).
Conclusion
A modified AIDA protocol for the treatment of childhood APL leads to improved EFS and 
OS, with limited ATRA syndrome-associated toxicity. Active monitoring and treatment 
of patients with high initial WBC counts may help in reducing mortality.
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INTRODUCTION
  Acute promyelocytic leukemia (APL) is different from 
other subtypes of acute myeloid leukemia (AML) because 
of the characteristic translocation between chromosomes 15 
and 17 [1]. This translocation includes a breakpoint in the 
retinoic acid receptor, which leads to the creation of the 
promyelocytic leukemia/retinoic acid receptor α fusion pro-
tein (PML-RARα) [2]. Clinically, the disease is characterized 
by thrombocytopenia because of bone marrow insufficiency 
and coagulopathy at diagnosis [3].
  As compared to other AML subtypes, APL responds well 
to anthracycline treatment. However, remission induction 
treatment consisting of anthracycline alone leads to early 
mortality from bleeding complications, which results in an 
overall lower complete remission (CR) rate than that for 
other AML subtypes.
  However, since the first reports on the vitamin A derivative 
all-trans-retinoic acid (ATRA) in China in 1988, the CR 
rate of APL has reached 90%, and ATRA efficacy has been 
further proven in several clinical studies [4-6]. However, Korean J Hematol 2010;45:236-41.
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Table 1. Patients characteristics.
Patient No. Age (years) Gender WBC (/μL)
a) Blasts (%)
a) Hb (g/dL)
a) Platelets (/μL)
a) Current status Survival (months)
1 14 M 1,200 20 3.6 13,000 1
st CR 132
2 2 F 1,400 2 5.4 39,000 1
st CR 123
3 8 M 146,000 94 9.0 34,000 Death 0.2
4 7 F 150,100 2 7.7 59,000 Death 0.1
5 14 M 6,400 20 9.9 44,000 1
st CR 92
6 12 F 68,400 81 6.9 21,000 Death 48
7 9 F 11,100 36 6.1 28,000 1
st CR 85
8 2 F 3,000 4 8.4 15,000 1
st CR 82
9 14 M 855 1 9.7 33,100 Death 13
10 10 F 7,560 75 4.8 10,000 1
st CR 79
11 10 F 1,300 3 7.9 8,000 1
st CR 78
12 6 M 840 83 10.2 83,000 Death 39
13 8 M 26,800 10 7.0 16,000 1
st CR 71
14 13 F 3,200 32 6.4 36,000 1
st CR 65
15 10 F 2,040 26 8.5 5,000 1
st CR 63
16 13 F 1,090 15 9.0 141,000 1
st CR 60
17 13 F 180,200 92 8.2 50,000 Death 0.2
18 11 F 1,650 18 9.7 22,000 1
st CR 55
19 8 M 16,150 62 9.4 23,000 1
st CR 45
20 12 M 3,600 70 5.8 40,000 1
st CR 37
21 11 M 30,850 79 8.9 13,000 1
st CR 29
22 13 M 8,510 83 6.8 15,000 1
st CR 30
23 11 M 6,980 84 9.6 25,000 1
st CR 29
a)Complete blood counts at initial diagnosis.
Abbreviation: CR, complete remission.
ATRA administered alone leads to a high rate of relapse 
within a year of CR, while ATRA combined with intensive 
chemotherapy results in improved CR rate and overall surviv-
al (OS) [6-8].  In 1996, Avvisati et al. [9] first introduced 
the AIDA (ATRA plus idarubicin) protocol, and since then, 
maintenance chemotherapy using ATRA has led to improved 
OS.
  In our institution we implemented a modified AIDA proto-
col for children newly diagnosed with APL; our protocol 
consisted of combined ATRA and anthracycline-based che-
motherapy for remission induction and consolidation, fol-
lowed by regular administration of ATRA during main-
tenance therapy. In this study, we analyzed the outcome 
of patients diagnosed with APL and treated according to 
the modified AIDA protocol at our institution.
MATERIALS AND METHODS
1. Patients
  Twenty-three patients diagnosed with APL from May, 
1999 to December, 2007 at the Department of Pediatrics, 
Saint Mary’s Hospital, the Catholic University of Korea, were 
included in the study. All patients were newly diagnosed, 
with morphology of bone marrow aspirate consistent with 
APL.  Fluorescent in situ hybridization (FISH), RT-PCR and 
immunophenotype studies were performed in all patients, 
and t(15;17)(q22;q12) was identified. Patients with iso-
chromosome 17 were also included in the study.
2. Treatment
  Patients newly diagnosed with APL were given ATRA 
at a dose of 45 mg/m
2/day divided in 2 doses. To prevent 
the occurrence of ATRA syndrome, oral dexamethasone was 
administered at a dose of 8 mg/m
2/day divided in 3 doses 
for 3 days from the start of ATRA. Idarubicin administration 
at a dose of 12 mg/m
2/day was started on day 2, and was 
also administered on days 4, 6, and 8 for a total of 4 doses.
  After remission induction, consolidation chemotherapy 
was initiated in a 3-step manner. During initial consolidation, 
cytarabine and idarubicin were administered for 4 consec-
utive days at doses of 1 g/m
2/day and 5 mg/m
2/day respec-
tively.  In the second step of consolidation, mitoxantrone 
10 mg/m
2/day was administered on days 1-5, and etoposide 
100 mg/m
2/day was administered on days 1-4. During the 
third and final steps of consolidation, idarubicin was ad-
ministered at a dose of 12 mg/m
2/day on day 1, and cytarabine 
at a dose of 100 mg/m
2/day on days 1-5.
  After each course of consolidation, bone marrow examina-
tion was performed to verify CR status. Maintenance chemo-
therapy was started after completion of consolidation therapy 
and included ATRA (45 mg/m
2/day) for 14 days every 
3-month period, oral methotrexate (20 mg/m
2/day) once 
weekly, and 6-mercaptopurine given daily (60 mg/m
2/day) 
for 2 years. Scheduled bone marrow examinations were also 
performed during maintenance therapy to assess CR status.Korean J Hematol 2010;45:236-41.
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Fig. 1. Age distribution of APL cohort. Median age at diagnosis was 11
years (range, 2-14).
Table 2. Classification of patient group according to relevant clinical and laboratory findings.
Median (range) N (%) CR rate (%) OS (%) P-value (CR rate/OS)
Number of patients 23 20 (87) 18 (76)
Age 11 (2-14) 0.658/0.723
＜10 11 (48) 9 (82) 9 (82)
≥10 12 (52) 11 (92) 9 (75)
Gender 0.786/0.830
Male 11 (48) 10 (91) 9 (82)
Female 12 (52) 10 (83) 9 (75)
WBC (×10
9/L)
a) 6.4 (0.8-180.2) 0.039/0.039
＜10 15 (65) 15 (100) 14 (93)
≥10 8 (35) 5 (63) 4 (50)
Circulating blasts (%)
a) 32 (1-94)
Platelets (×10
9/L)
a) 25 (5-141) 0.564/NA
≤20 8 (35) 8 (100) 8 (100)
＞20 15 (65) 12 (80) 10 (67)
Hb (g/dL)
a) 8.2 (3.6-10.2)
≤10 22 (96) 19 (83) 17 (77)
＞10 1 (4) 1 (100) 1 (100)
Cytogenetics
Normal 2 (8) 1 (50) 1 (50)
t(15;17) 14 (62) 12 (86) 11 (79)
t(15;17)+others 5 (22) 5 (100) 5 (100)
i(17) 2 (8) 2 (100) 1 (50)
Clinical signs
Fever 14 (62) 12 (86) 10 (71)
Organomegaly 8 (35) 6 (75) 4 (50)
Hemorrhage
Cutaneous 7 (30) 6 (86) 4 (57)
Mucosal 7 (30) 7 (100) 7 (100)
CNS 3 (13) 0 (0) 0 (0)
Other 1 (4) 1 (100) 1 (100)
ATRA syndrome 4 (17) 3 (75) 3 (75)
Fever/cough 1 (4) 0 (0) 0 (0)
Headache 2 (8) 2 (100) 2 (100)
Pleural effusion 1 (4) 1 (100) 1 (100)
a)Complete blood counts at initial diagnosis.
Abbreviations: ATRA, all-trans-retinoic acid; CR, complete remission; OS, overall survival; NA, not applicable.
3. Study design
  A retrospective analysis of the clinical course of patients 
was performed. Basic demographics were recorded, along 
with dates of first complete remission, relapse and death. 
Cytogenetic abnormalities as diagnosed on metaphase bone 
marrow chromosomal studies were recorded. In addition 
the presence of ATRA syndrome during treatment was noted. 
ATRA syndrome was defined as the presence of at least 
3 of the following signs concurrent with the administration 
of ATRA in the absence of other causes: fever, weight gain, 
respiratory distress, lung infiltrates, pleural or pericardial 
effusion, hypotension, and renal failure [8]. The analyses 
were performed as of April 30
th, 2010.
4. Statistical analysis
  Chi-square test was used to compare categorical variables.  
Event-free survival (EFS) and OS were calculated using the 
Kaplan-Meier method, and analysis of risk factors for CR Korean J Hematol 2010;45:236-41.
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Fig. 2. Outcome of APL cohort treated using modified AIDA protocol.
Fig. 4. Overall survival of APL cohort according to initial WBC count at 
diagnosis.
Fig. 3. Overall survival of APL cohort.
rate and OS was done using the Cox proportional hazards 
model.  For multivariate analysis, factors known to affect 
clinical outcome, such as age, gender, initial WBC count 
and platelet count, were entered into the model. P-values 
＜0.05 were regarded as statistically significant.
RESULTS
1. Study cohort and diagnosis of APL
1) Study cohort
  The major characteristics of the 23 patients are outlined 
in Table 1. Apart from 1 patient who had been previously 
diagnosed with Fanconi anemia, none of the others had 
a known history of hematologic disease at diagnosis. The 
Fanconi anemia patient has completed the treatment for 
APL, and is currently alive with no major events. Eleven 
patients were males (48%) and 12 were females (52%). 
Median age at diagnosis was 11 years (range, 2-14). The 
age distribution of the patients is shown in Fig. 1.
2) Diagnosis
  The most common signs or symptoms at diagnosis were 
bleeding tendency (N=18, 78%), fever (N=14, 61%), and hep-
atosplenomegaly (N=8, 35%). The median WBC count at 
diagnosis was 6,400/μL (range, 840-180,200), with 15 patients 
(65%) presenting with an initial WBC count ＜10,000/μL, 
and 8 patients (35%) ≥10,000/μL (Table 2).
  Chromosomal studies showed a normal karyotype in 2 
patients (8%) (Table 2), who were diagnosed by bone marrow 
aspiration morphology and by identification of PML/RARα 
fusion gene with FISH studies. Isochromosome 17, which 
has been associated with a poor prognosis [10, 11], was identi-
fied in 2 patients, one of whom relapsed and died. 
2. Treatment of APL
1) Clinical course of treatment
  Three patients died after initiation of remission induction 
chemotherapy (13%), the cause of early death being CNS 
hemorrhage in all cases. One patient died after a single in-
fusion of idarubicin, while the remaining 2 patients died 
before the initiation of anthracycline chemotherapy. The 
average duration of survival after diagnosis was 4.3 days 
(range, 3-7) in these 3 patients.
  After initial remission induction treatment, 19 of the surviv-
ing 20 patients achieved CR (83%). The remaining patient 
was found to have 50% myeloblasts on follow-up bone mar-
row study, but progressed to the first cycle of consolidation, 
after which CR was diagnosed. Hence, overall CR rate was 
8 7 %  w i t h  a  m e d i a n  d u r a t i o n  o f  3 3  d a y s  t i l l  d i a g n o s i s  o f  Korean J Hematol 2010;45:236-41.
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CR (range, 27-79) (Table 2).
  A total of 20 patients completed the consolidation phase 
of treatment and progressed to the maintenance phase. Three 
of these 20 patients died; 1 patient relapsed after 12 months 
of maintenance treatment and died during reinduction 
treatment. One patient relapsed 28 months after the end 
of treatment, achieved a second CR, but showed CNS relapse 
6 months later. The patient underwent autologous stem cell 
transplantation without achieving a third CR, and died of 
sepsis afterwards. Another patient died of pneumonia 70 
days after completing treatment for APL. The remaining 
17 patients are alive without relapse, and their course is 
being followed (Fig. 2). 
2) ATRA syndrome 
  ATRA syndrome was diagnosed in 4 patients (17%) (Table 
2), 3 patients during remission induction and the remaining 
1 patient during maintenance treatment. One patient who 
presented with fever and cough showed improved symptoms 
after the tapering of ATRA dosage, while another patient 
who showed pleural effusion was given a second course 
of dexamethasone. The 2 patients who complained of head-
ache, one of whom experienced ATRA syndrome during 
maintenance chemotherapy, were both treated with dexa-
methasone.
3. Clinical endpoints and prognostic variables
  The EFS of the cohort was 78.3±8.6%. Similarly, the OS 
was 76.3±9.5% (Fig. 3), with a median duration of survival 
of 61.5 months (range, 13-132) excluding the 3 patients who 
experienced early death. The initial WBC count proved to 
be significant for the prognosis of CR (P=0.039), while other 
variables such as age, gender, and initial platelet count did 
not have a significant impact on univariate study. The multi-
variate analysis confirmed that the initial WBC count was 
the only factor with statistical significance on CR (HR 5.49, 
95% CI 1.40-21.55, P=0.015). Similarly, WBC count was 
the only factor with statistical significance on OS (P=0.039) 
as shown by univariate analysis and Kaplan-Meier survival 
estimate (Fig. 4).
DISCUSSION
  The main purpose of our study was to investigate the 
rates of CR and OS of children diagnosed with APL, who 
were treated with a combined ATRA and chemotherapy 
regimen incorporated into initial remission induction, con-
solidation and maintenance therapy.
  In children, EFS and OS rates of AML are reported to 
be 45±4% and 56±4% respectively, which are lower than 
those reported for ALL [12]. APL comprises 8-12% of pedia-
tric AML, and, as in the adult population, is characterized 
by disseminated intravascular coagulation resulting in bleed-
ing and death [13, 14].
  Since the introduction of ATRA, a combined chemo-
therapeutic approach using ATRA and other anti-neoplastic 
agents has been implemented, resulting in CR rates of 86- 
92% and EFS rates of 62-82%, as has been shown by the 
European APL study, the GIMEMA and PETHEMA studies 
[8, 15, 16]. Furthermore, clinical research has shown positive 
effects of ATRA in resolving the bleeding tendency inherent 
in newly diagnosed APL. Since 1999, we have treated APL 
patients with ATRA and idarubicin, according to the AIDA 
protocol, which has resulted in high EFS and OS rates for 
children with APL [15]. The results of our study, which 
included patients treated during a 9 year period also corrobo-
rate the efficacy of this regimen with high CR (87%) and 
OS (76%) rates.
  Previous studies on risk factors in APL have highlighted 
the importance of initial WBC and platelet counts, as well 
as patient gender on overall prognosis [17, 18]. However, 
in our study initial WBC count was found as the only variable 
with prognostic significance in multivariate analysis.
  Early after initiation of treatment, 3 patients died of CNS 
hemorrhage comprising 60% of disease-related mortality. 
Aggressive prevention and treatment of bleeding at the be-
ginning of chemotherapy remains a key factor in overall 
treatment success.
  APL is characterized by a translocation between chromo-
somes 15 and 17, which results in the fusion of PML gene 
on the long arm of chromosome 15 with RARα gene on 
the long arm of chromosome 17. A variant of this trans-
location is isochromosome 17, and patients with this variant 
were also included in this study. Isochromosome 17 is rarely 
reported in the literature, but is known to have a poor prog-
nosis in the adult population [19, 20]. However, the limited 
number of patients with this chromosomal variant in our 
study precluded the possibility of making definite con-
clusions on this subject.
  Complications resulting from ATRA treatment are com-
monly referred to as “ATRA syndrome,” an entity that in-
cludes leukocytosis, fever, weight gain, respiratory failure, 
pleural or pericardial effusion, and renal failure [21, 22]. 
The reported incidence of ATRA syndrome varies from 2% 
to 30%, with a mortality of 1-8% [23, 24]. Treatment options 
for this complication include a reduction in the dose of 
ATRA or coadministration of dexamethasone [24, 25]; in 
our modified AIDA protocol, dexamethasone was con-
comitantly administered for 3 days after the start of ATRA 
as a prophylaxis of ATRA syndrome. As a result, ATRA 
syndrome was diagnosed in 4 patients, including 3 patients 
in remission induction, which indicated the potential efficacy 
of dexamethasone for the prevention of ATRA syndrome. 
Signs and symptoms of the ATRA syndrome were mild head-
ache, pleural effusion, fever and cough, but all patients 
showed resolution of the symptoms after either restarting 
dexamethasone or decreasing ATRA dosage.
  Our results, derived from a small cohort of patients, in-
dicate that combination of ATRA and chemotherapy during 
both remission induction and maintenance therapy led to 
high rates of CR and OS, consistent with the results that 
have previously been reported. Active prevention of CNS 
bleeding during the initiation of treatment may limit early 
mortality, while identification of patients with high initial Korean J Hematol 2010;45:236-41.
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WBC counts as a high-risk group may lead to superior surviv-
al outcomes. The limited number of pediatric patients in 
this study, when compared to those done on the adult pop-
ulation, emphasize the need for a larger scale study in order 
to draw conclusions about the impact of significant risk 
factors, such as ATRA syndrome, on clinical endpoints.
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